Mass. doctor leads new type of cell therapy offering hope to lupus patients
CAR-T cell therapy, a marvel of bioengineering, takes a patient’s own immune cells and reprograms them to attack cells causing Lupus. First approved for treating leukemia in 2017, CAR-T cell therapy ...
Cure Today11h
CAR T-Cell Therapy Yescarta Continues to Demonstrate Durable Responses in Follicular Lymphoma
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma.
The American Journal of Managed Care12h
Gene Therapy Demonstrates High Efficacy in Severe β-Thalassemia
A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β ...
Scientists unveil surprising human vs. mouse differences in a major cancer immunotherapy target
Since its discovery in the 1990s, programmed cell death protein 1 (PD-1) has been regarded as a leading target in cancer ...
The American Journal of Managed Care12h
New Generation of CAR T May Elicit Improved CR Rates in CLL
T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic ...
AZoLifeSciences on MSN15h
Unveiling the Impact of Antigen History on CAR-T Cell Function
The memory of previous interactions with bacteria, viruses, and other antigens is carried by some CAR-T cells that have been engineered to fight cancer and other conditions, according to research from ...
Bioengineers develop construction kit for 'smart cell' design
Rice University bioengineers have developed a new construction kit for building custom sense-and-respond circuits in human ...